Here's What You May Have Missed About BeiGene(BGNE)

By Susan Ramirez • Wednesday, March 13 10:15 • Permanent Link

With gains of 8.1%, BeiGene was one of the winners on Wall Street today. Its shares are now trading at $177.07 and have logged a -0.0% daily outperformance of the S&P 500. Don't join the feeding frenzy before checking some basic facts about this stock:

BeiGene has moved -30.6% over the last year, and the S&P 500 logged a change of 33.0%
BGNE has an average analyst rating of buy and is -35.52% away from its mean target price of $274.63 per share
Its trailing earnings per share (EPS) is $-8.45
BeiGene has a trailing 12 month Price to Earnings (P/E) ratio of -21.0 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $-3.7 and its forward P/E ratio is -47.9
The company has a Price to Book (P/B) ratio of 5.23 in contrast to the S&P 500's average ratio of 2.95
BeiGene is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
The company has a free cash flow of $-1271425024, which refers to the total sum of all its inflows and outflows of cash over the last quarter
BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.